AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
- Conditions
- Gastric Ulcer
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00428701
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
🇺🇸Research SIte, Newark, Delaware, United States
Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients
- Conditions
- GERD
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2010-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT00427635
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
- Conditions
- Hypercholesterolaemia
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT00427960
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
🇬🇧Research SIte, Slough, United Kingdom
Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 743
- Registration Number
- NCT00424268
- Locations
- 🇬🇧
Altana Pharma/Nycomed Investigational Site, Yaxley, United Kingdom
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT00423332
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
- Conditions
- Manic StateAffective Psychosis, BipolarManic DisorderManic-Depressive PsychosisManiaPsychoses, Manic-Depressive
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 447
- Registration Number
- NCT00422123
- Locations
- 🇺🇸
Research Sitew, Fort Lauderdale, Florida, United States
🇺🇸Research Site, Bellevue, Washington, United States
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
- Conditions
- Affective Psychosis, BipolarDepression, BipolarManic-Depressive PsychosisPsychoses, Manic-Depressive
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00422214
- Locations
- 🇺🇸
Research Site, South Kirkland, Washington, United States
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT00421122
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
- Conditions
- Asthma
- Interventions
- Drug: Budesonide/formoterol (SYMBICORT) pMDI
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-08-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 558
- Registration Number
- NCT00419757
- Locations
- 🇵🇷
Research Site, Trujillo Alto, Puerto Rico
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
- Conditions
- Asthma
- Interventions
- Drug: Budesonide/formoterol (SYMBICORT) pMDI
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 742
- Registration Number
- NCT00419952
- Locations
- 🇺🇸
Research Site, Springfield, Virginia, United States